PM3023 / BioNTech - LARVOL DELTA

Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy (SITC 2022) - "CLDN18.2-CAB-T is currently undergoing an investigator-initiated trial to test its safety and efficacy for subjects with CLDN18.2+ solid tumors. Ethics Approval All mice were maintained under specified pathogen-free conditions, and all studies were approved by the Animal Care and Use Committee of HUST-Suzhou Institute for Brainsmatics."

IO biomarker • Preclinical • Oncology • Solid Tumor • CLDN18 • CLDN8 • CSF2 • IFNG • IL2 • IL6 • TNFA